Conference Coverage: American Society of Hematology (ASH): Annual Meeting

Conference Coverage

Chemo-free induction regimen shines in MCL

SAN DIEGO – A chemotherapy-free induction regimen of ibrutinib and rituximab was well tolerated and achieved an overall response rate of 100%...

Conference Coverage

Ibrutinib continues to wow in CLL/SLL

SAN DIEGO – More than 90% of the first patients with previously untreated chronic lymphocytic leukemia who received ibrutinib in an early study...